13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001839948
Total reported value
$4.2B
$4.2B
49 檔
37.3%
As reported in its official Q1 2026 Form 13F filing, TCG Crossover Management, LLC's tracked investment portfolio stood at $4.2B with 49 total positions.
In Q1 2026, TCG Crossover Management, LLC displayed an active expansion posture, initiating 11 new positions and adding to 8 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ABVX | Abivax Sa-adr | Stock-Other | 20.65% | -1.41% | -8.87% | |
| 2 | CGON | Cg Oncology Inc | Stock-Other | 7.11% | -0.84% | — | |
| 3 | TNGX | Tango Therapeutics Inc | Stock-Other | 6.30% | +0.52% | -17.48% | |
| 4 | COGT | Cogent Biosciences Inc | Stock-Other | 5.45% | -0.93% | -15.70% | |
| 5 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 4.87% | -4.87% | EXIT | |
| 6 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 4.03% | -0.10% | — | |
| 7 | TYRA | Tyra Biosciences Inc | Stock-Other | 3.56% | -1.07% | +12.11% | |
| 8 | IMVT | Immunovant Inc | Stock-Other | 3.17% | +0.96% | +168.40% | |
| 9 | BCRX | Biocryst Pharmaceuticals Inc | Stock-Other | 3.00% | -0.35% | — | |
| 10 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 2.81% | +0.18% | +1611.63% | |
| 11 | VOR | Vor Biopharma Inc | Stock-Other | 2.76% | -0.25% | — | |
| 12 | SYRE | Spyre Therapeutics Inc | Stock-Other | 2.74% | +1.32% | — | |
| 13 | AMLX | Amylyx Pharmaceuticals Inc | Stock-Other | 2.48% | +0.22% | — | |
| 14 | IRON | Disc Medicine Inc | Stock-Other | 2.45% | -0.09% | — | |
| 15 | DYN | Dyne Therapeutics Inc | Stock-Other | 2.39% | +0.07% | — | |
| 16 | GLUE | Monte Rosa Therapeutics Inc | Stock-Other | 2.18% | +0.51% | — | |
| 17 | SVRA | Savara Inc | Stock-Other | 1.93% | -0.10% | — | |
| 18 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 1.60% | -0.07% | +32.08% | |
| 19 | KOD | Kodiak Sciences Inc | Stock-Other | 1.58% | -0.23% | — | |
| 20 | LBRX | Lb Pharmaceuticals Inc | Stock-Other | 1.30% | -0.17% | +5.41% | |
| 21 | SRZN | Surrozen Inc | Stock-Other | 1.23% | -0.31% | — | |
| 22 | ✓ | Adc Therapeutics SA | Stock-Other | 1.22% | -0.93% | — | |
| 23 | RLAY | Relay Therapeutics Inc | Stock-Other | 1.22% | +0.70% | +32.71% | |
| 24 | FULC | Fulcrum Therapeutics Inc | Stock-Other | 1.15% | -1.15% | EXIT | |
| 25 | BHVN | Biohaven Ltd. | Stock-Other | 1.12% | -0.48% | — | |
| 26 | IPSC | Century Therapeutics Inc | Stock-Other | 1.12% | -0.08% | — | |
| 27 | TECX | Tectonic Therapeutic Inc | Stock-Other | 1.07% | -0.07% | — | |
| 28 | CATX | Perspective Therapeutics Inc | Stock-Other | 0.94% | -0.29% | — | |
| 29 | XNCR | Xencor Inc | Stock-Other | 0.85% | +0.10% | — | |
| 30 | TRDA | Entrada Therapeutics Inc | Stock-Other | 0.83% | -0.64% | +9.53% | |
| 31 | ALXO | Alx Oncology Holdings Inc | Stock-Other | 0.75% | -0.47% | — | |
| 32 | ARVN | Arvinas Inc | Stock-Other | 0.72% | -0.58% | -10.46% | |
| 33 | JANX | Janux Therapeutics Inc | Stock-Other | 0.71% | -0.05% | — | |
| 34 | AGMB | Agomab Therapeutics NV | Stock-Other | 0.62% | +0.02% | — | |
| 35 | ALEC | Alector Inc | Stock-Other | 0.62% | -0.14% | — | |
| 36 | MBX | Mbx Biosciences Inc | Stock-Other | 0.56% | +0.30% | — | |
| 37 | SLN | Silence Therapeutics Plc-adr | Stock-Other | 0.46% | +0.34% | — | |
| 38 | LQDA | Liquidia CORP | Stock-Other | 0.44% | -0.44% | EXIT | |
| 39 | OCUL | Ocular Therapeutix Inc | Stock-Other | 0.40% | -0.01% | -71.29% | |
| 40 | AVTX | Avalo Therapeutics Inc | Stock-Other | 0.32% | +1.02% | +52.87% | |
| 41 | URGN | UroGen Pharma Ltd. | Stock-Other | 0.21% | -0.21% | EXIT | |
| 42 | MNPR | Monopar Therapeutics Inc | Stock-Other | 0.21% | +0.24% | -6.91% | |
| 43 | CNTX | Context Therapeutics Inc | Stock-Other | 0.20% | -0.16% | — | |
| 44 | GPCR | Structure Therapeutics Inc | Stock-Other | 0.19% | -0.19% | EXIT | |
| 45 | CGEM | Cullinan Therapeutics Inc | Stock-Other | 0.17% | +0.01% | — | |
| 46 | KRRO | Korro Bio Inc | Stock-Other | 0.13% | — | — | |
| 47 | LONA | Leonabio Inc | Stock-Other | 0.13% | -0.03% | — | |
| 48 | UPB | Upstream Bio Inc | Stock-Other | 0.05% | -0.05% | EXIT | |
| 49 | VTGN | Vistagen Therapeutics Inc | Stock-Other | 0.04% | -0.04% | EXIT |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | MIRM | Mirum Pharmaceuticals Inc | +2.7% | +1611.63% | Add |
| 2 | TNGX | Tango Therapeutics Inc | +2.6% | -17.48% | Trim |
| 3 | CGON | Cg Oncology Inc | +2.1% | — | Unchanged |
| 4 | IMVT | Immunovant Inc | +1.8% | +168.40% | Add |
| 5 | DNTH | Dianthus Therapeutics Inc | +1.7% | — | Unchanged |
| 6 | 260 | Centessa Pharmaceuticals-adr | +1.3% | — | Unchanged |
| 7 | TYRA | Tyra Biosciences Inc | +1% | +12.11% | Add |
| 8 | SYRE | Spyre Therapeutics Inc | +0.7% | — | Unchanged |
| 9 | RVMD | Revolution Medicines Inc | +0.5% | +32.08% | Add |
| 10 | RLAY | Relay Therapeutics Inc | +0.3% | +32.71% | Add |
| 11 | KOD | Kodiak Sciences Inc | +0.2% | — | Unchanged |
| 12 | TRDA | Entrada Therapeutics Inc | +0.1% | +9.53% | Add |
| 13 | ALEC | Alector Inc | +0.1% | — | Unchanged |
| 14 | AVTX | Avalo Therapeutics Inc | 0% | +52.87% | Add |
| 15 | KRRO | Korro Bio Inc | 0% | — | Unchanged |
| 16 | LONA | Leonabio Inc | 0% | — | Unchanged |
| 17 | LBRX | Lb Pharmaceuticals Inc | 0% | +5.41% | Add |
| 18 | AMLX | Amylyx Pharmaceuticals Inc | 0% | — | Unchanged |
| 19 | VTGN | Vistagen Therapeutics Inc | 0% | — | Unchanged |
| 20 | MNPR | Monopar Therapeutics Inc | -0.1% | -6.91% | Trim |
| 21 | ✓ | Adc Therapeutics SA | -0.1% | — | Unchanged |
| 22 | JANX | Janux Therapeutics Inc | -0.1% | — | Unchanged |
| 23 | MBX | Mbx Biosciences Inc | -0.1% | — | Unchanged |
| 24 | SLN | Silence Therapeutics Plc-adr | -0.2% | — | Unchanged |
| 25 | GLUE | Monte Rosa Therapeutics Inc | -0.2% | — | Unchanged |
| 26 | ARVN | Arvinas Inc | -0.3% | -10.46% | Trim |
| 27 | URGN | UroGen Pharma Ltd. | -0.4% | -43.49% | Trim |
| 28 | XNCR | Xencor Inc | -0.4% | — | Unchanged |
| 29 | SVRA | Savara Inc | -0.5% | — | Unchanged |
| 30 | DYN | Dyne Therapeutics Inc | -0.6% | — | Unchanged |
| 31 | BHVN | Biohaven Ltd. | -0.6% | — | Unchanged |
| 32 | UPB | Upstream Bio Inc | -0.6% | -75.66% | Trim |
| 33 | FULC | Fulcrum Therapeutics Inc | -0.8% | — | Unchanged |
| 34 | COGT | Cogent Biosciences Inc | -1.5% | -15.70% | Trim |
| 35 | LQDA | Liquidia CORP | -1.5% | -76.43% | Trim |
| 36 | OCUL | Ocular Therapeutix Inc | -1.9% | -71.29% | Trim |
| 37 | GPCR | Structure Therapeutics Inc | -1.9% | -84.75% | Trim |
| 38 | ABVX | Abivax Sa-adr | -11.1% | -8.87% | Trim |
| 39 | BCRX | Biocryst Pharmaceuticals Inc | — | NEW | New buy |
| 40 | VOR | Vor Biopharma Inc | — | NEW | New buy |
| 41 | RAPT | Rapt Therapeutics Inc | — | EXIT | Sold out |
| 42 | IRON | Disc Medicine Inc | — | NEW | New buy |
| 43 | EYPT | Eyepoint Inc | — | EXIT | Sold out |
| 44 | SRZN | Surrozen Inc | — | NEW | New buy |
| 45 | IPSC | Century Therapeutics Inc | — | NEW | New buy |
| 46 | TECX | Tectonic Therapeutic Inc | — | NEW | New buy |
| 47 | CATX | Perspective Therapeutics Inc | — | NEW | New buy |
| 48 | AGIO | Agios Pharmaceuticals Inc | — | EXIT | Sold out |
| 49 | ALXO | Alx Oncology Holdings Inc | — | NEW | New buy |
| 50 | AGMB | Agomab Therapeutics NV | — | NEW | New buy |
According to official SEC Form 13F filings, TCG Crossover Management, LLC reported a total U.S. public equity portfolio value of $4.2B across 49 disclosed positions in Q1 2026.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ABVX, CGON, TNGX) accounted for 37.3% of total reported equity market value during Q1 2026.
Top New Position Initiated
BCRX
市值: $104.9M
Top Position Liquidated / Trimmed
RAPT
前期市值: $87.5M
During Q1 2026, TCG Crossover Management, LLC's top holdings by market value included ABVX (20.6%)、CGON (7.1%)、TNGX (6.3%). The largest single position, ABVX, represented 20.6% of total portfolio value.
In Q1 2026, TCG Crossover Management, LLC made 34 total portfolio adjustments, initiating 11 new buys, adding to 8 positions, trimming 10 holdings, and fully liquidating 5 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.